Is MRKR or IBIO more profitable?

iBio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. iBio's return on equity of -40.66% beat Marker Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Marker Therapeutics -343.03% -56.96% -47.82% iBio N/A -40.66% -35.78%

Do analysts prefer TELO or MRKR?

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend BRTX or MRKR?

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Marker Therapeutics (MRKR) Competitors

$1.15 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.19 +0.04 (+3.13%)

As of 07:09 AM Eastern

Compare

MRKR vs. IBIO, CTOR, TELO, BRTX, and GANX

Should you buy Marker Therapeutics stock or one of its competitors? Marker Therapeutics's main competitors and comparable companies include iBio (IBIO), Citius Oncology (CTOR), Telomir Pharmaceuticals (TELO), Biorestorative Therapies (BRTX), and Gain Therapeutics (GANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Marker Therapeutics compare to iBio?

Marker Therapeutics (NASDAQ:MRKR) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

iBio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. iBio's return on equity of -40.66% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
iBio	N/A	-40.66%	-35.78%

Marker Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 769.57%. iBio has a consensus target price of $5.00, indicating a potential upside of 314.94%. Given Marker Therapeutics' higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 1.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Marker Therapeutics has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	5.40	-$12.16M	-$0.41	N/A
iBio	$100K	774.94	-$33.04M	-$0.34	N/A

In the previous week, iBio had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for iBio and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.87 beat iBio's score of 0.40 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Very Positive
iBio	Neutral

Marker Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, iBio has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Summary

iBio beats Marker Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Marker Therapeutics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Citius Oncology has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

In the previous week, Citius Oncology and Citius Oncology both had 1 articles in the media. Citius Oncology's average media sentiment score of 1.87 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Citius Oncology	Very Positive
Marker Therapeutics	Very Positive

Citius Oncology currently has a consensus target price of $6.00, suggesting a potential upside of 553.95%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 769.57%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics has higher revenue and earnings than Citius Oncology. Marker Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Marker Therapeutics	$3.55M	5.40	-$12.16M	-$0.41	N/A

Citius Oncology has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Marker Therapeutics	-343.03%	-56.96%	-47.82%

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Citius Oncology beats Marker Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Marker Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 1.87 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Marker Therapeutics	Very Positive

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Telomir Pharmaceuticals has higher earnings, but lower revenue than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Marker Therapeutics	$3.55M	5.40	-$12.16M	-$0.41	N/A

Telomir Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Marker Therapeutics	-343.03%	-56.96%	-47.82%

22.4% of Marker Therapeutics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Marker Therapeutics beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Biorestorative Therapies and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.87 beat Biorestorative Therapies' score of 0.96 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biorestorative Therapies	Positive
Marker Therapeutics	Very Positive

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Marker Therapeutics has higher revenue and earnings than Biorestorative Therapies. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	10.24	-$14.24M	-$1.07	N/A
Marker Therapeutics	$3.55M	5.40	-$12.16M	-$0.41	N/A

Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics has a net margin of -343.03% compared to Biorestorative Therapies' net margin of -3,088.27%. Marker Therapeutics' return on equity of -56.96% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Marker Therapeutics	-343.03%	-56.96%	-47.82%

Summary

Marker Therapeutics beats Biorestorative Therapies on 11 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Gain Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Gain Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -56.96% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
Gain Therapeutics	N/A	-161.59%	-118.36%

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 769.57%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 328.57%. Given Marker Therapeutics' higher possible upside, equities research analysts plainly believe Marker Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Gain Therapeutics had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.87 beat Gain Therapeutics' score of 1.15 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Very Positive
Gain Therapeutics	Positive

Marker Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	5.40	-$12.16M	-$0.41	N/A
Gain Therapeutics	$50K	1,527.40	-$20.16M	-$0.50	N/A

Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Summary

Marker Therapeutics beats Gain Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.17M	$3.84B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.80	14.25	275.28	25.35
Price / Sales	5.40	1,418.81	646.14	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.14	15.23	10.37	6.21
Net Income	-$12.16M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-2.54%	-4.37%	-3.30%	-2.39%
1 Month Performance	0.88%	-0.66%	-0.86%	-3.39%
1 Year Performance	20.47%	40.76%	23.53%	8.81%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	3.0475 of 5 stars	$1.15 flat	$10.00 +769.6%	+20.5%	$19.17M	$3.55M	N/A	60	Positive News Gap Up
IBIO iBio	2.2318 of 5 stars	$1.31 -0.4%	$5.00 +283.1%	N/A	$83.93M	$100K	N/A	100	Analyst Downgrade
CTOR Citius Oncology	2.0265 of 5 stars	$0.90 +4.4%	$6.00 +568.2%	-52.0%	$83.50M	N/A	N/A	N/A	Positive News Gap Down
TELO Telomir Pharmaceuticals	0.4714 of 5 stars	$1.21 +4.3%	N/A	-14.0%	$83.22M	N/A	N/A	1	News Coverage
BRTX Biorestorative Therapies	0.9748 of 5 stars	$2.90 -1.9%	N/A	-91.3%	$80.18M	$360K	N/A	7	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. IBIO, CTOR, TELO, BRTX, and GANX

How does Marker Therapeutics compare to iBio?

Summary

How does Marker Therapeutics compare to Citius Oncology?

Summary

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Marker Therapeutics compare to Biorestorative Therapies?

Summary

How does Marker Therapeutics compare to Gain Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. IBIO, CTOR, TELO, BRTX, and GANX

How does Marker Therapeutics compare to iBio?

Is MRKR or IBIO more profitable?

Do analysts rate MRKR or IBIO?

Do institutionals and insiders have more ownership in MRKR or IBIO?

Which has higher valuation and earnings, MRKR or IBIO?

Does the media refer more to MRKR or IBIO?

Which has more risk & volatility, MRKR or IBIO?

Summary

How does Marker Therapeutics compare to Citius Oncology?

Which has more risk & volatility, CTOR or MRKR?

Does the media prefer CTOR or MRKR?

Do analysts prefer CTOR or MRKR?

Which has stronger valuation & earnings, CTOR or MRKR?

Is CTOR or MRKR more profitable?

Do institutionals & insiders believe in CTOR or MRKR?

Summary

How does Marker Therapeutics compare to Telomir Pharmaceuticals?

Which has more volatility & risk, TELO or MRKR?

Does the media prefer TELO or MRKR?

Do analysts prefer TELO or MRKR?

Which has higher earnings and valuation, TELO or MRKR?

Is TELO or MRKR more profitable?

Do institutionals and insiders believe in TELO or MRKR?

Summary

How does Marker Therapeutics compare to Biorestorative Therapies?

Does the media prefer BRTX or MRKR?

Do institutionals and insiders have more ownership in BRTX or MRKR?

Which has preferable valuation & earnings, BRTX or MRKR?

Which has more volatility and risk, BRTX or MRKR?

Do analysts recommend BRTX or MRKR?

Is BRTX or MRKR more profitable?

Summary

How does Marker Therapeutics compare to Gain Therapeutics?

Is MRKR or GANX more profitable?

Do analysts rate MRKR or GANX?

Do institutionals & insiders believe in MRKR or GANX?

Does the media favor MRKR or GANX?

Which has higher valuation and earnings, MRKR or GANX?

Which has more volatility and risk, MRKR or GANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools